Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Development of Influenza B Universal Vaccine Candidates using the "Mosaic" Hemagglutinin Approach.

Sun W, Kirkpatrick E, Ermler M, Nachbagauer R, Broecker F, Krammer F, Palese P.

J Virol. 2019 Apr 3. pii: JVI.00333-19. doi: 10.1128/JVI.00333-19. [Epub ahead of print]

PMID:
30944178
2.

Erratum: Sunwoo, S.-Y. et al. A Universal Influenza Virus Vaccine Candidate Tested in a Pig Vaccination-Infection Model in the Presence of Maternal Antibodies. Vaccines 2018, 6(3), 64.

Sunwoo SY, Schotsaert M, Morozov I, Davis AS, Li Y, Lee J, McDowell C, Meade P, Nachbagauer R, García-Sastre A, Ma W, Krammer F, Richt JA.

Vaccines (Basel). 2018 Nov 27;6(4). pii: E80. doi: 10.3390/vaccines6040080.

3.

A Universal Influenza Virus Vaccine Candidate Tested in a Pig Vaccination-Infection Model in the Presence of Maternal Antibodies.

Sunwoo SY, Schotsaert M, Morozov I, Davis AS, Li Y, Lee J, McDowell C, Meade P, Nachbagauer R, García-Sastre A, Ma W, Krammer F, Richt JA.

Vaccines (Basel). 2018 Sep 14;6(3). pii: E64. doi: 10.3390/vaccines6030064.

4.

Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance.

Liu STH, Behzadi MA, Sun W, Freyn AW, Liu WC, Broecker F, Albrecht RA, Bouvier NM, Simon V, Nachbagauer R, Krammer F, Palese P.

J Clin Invest. 2018 Nov 1;128(11):4992-4996. doi: 10.1172/JCI122895. Epub 2018 Oct 8.

5.

Assessment of Influenza Virus Hemagglutinin Stalk-Specific Antibody Responses.

Liu WC, Nachbagauer R, Krammer F, Albrecht RA.

Methods Mol Biol. 2018;1836:487-511. doi: 10.1007/978-1-4939-8678-1_23.

PMID:
30151588
6.
7.

Cross-reactive mouse monoclonal antibodies raised against the hemagglutinin of A/Shanghai/1/2013 (H7N9) protect against novel H7 virus isolates in the mouse model.

Stadlbauer D, Amanat F, Strohmeier S, Nachbagauer R, Krammer F.

Emerg Microbes Infect. 2018 Jun 20;7(1):110. doi: 10.1038/s41426-018-0115-0.

8.

Broadly Reactive Human Monoclonal Antibodies Elicited following Pandemic H1N1 Influenza Virus Exposure Protect Mice against Highly Pathogenic H5N1 Challenge.

Nachbagauer R, Shore D, Yang H, Johnson SK, Gabbard JD, Tompkins SM, Wrammert J, Wilson PC, Stevens J, Ahmed R, Krammer F, Ellebedy AH.

J Virol. 2018 Jul 31;92(16). pii: e00949-18. doi: 10.1128/JVI.00949-18. Print 2018 Aug 15.

9.

Development of next generation hemagglutinin-based broadly protective influenza virus vaccines.

Nachbagauer R, Palese P.

Curr Opin Immunol. 2018 Aug;53:51-57. doi: 10.1016/j.coi.2018.04.001. Epub 2018 Apr 20. Review.

PMID:
29680576
10.

An immuno-assay to quantify influenza virus hemagglutinin with correctly folded stalk domains in vaccine preparations.

Rajendran M, Sun W, Comella P, Nachbagauer R, Wohlbold TJ, Amanat F, Kirkpatrick E, Palese P, Krammer F.

PLoS One. 2018 Apr 4;13(4):e0194830. doi: 10.1371/journal.pone.0194830. eCollection 2018.

11.

A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies.

Nachbagauer R, Liu WC, Choi A, Wohlbold TJ, Atlas T, Rajendran M, Solórzano A, Berlanda-Scorza F, García-Sastre A, Palese P, Albrecht RA, Krammer F.

NPJ Vaccines. 2017 Sep 14;2:26. doi: 10.1038/s41541-017-0026-4. eCollection 2017.

12.

Vaccination with a Recombinant H7 Hemagglutinin-Based Influenza Virus Vaccine Induces Broadly Reactive Antibodies in Humans.

Stadlbauer D, Rajabhathor A, Amanat F, Kaplan D, Masud A, Treanor JJ, Izikson R, Cox MM, Nachbagauer R, Krammer F.

mSphere. 2017 Dec 13;2(6). pii: e00502-17. doi: 10.1128/mSphere.00502-17. eCollection 2017 Nov-Dec.

13.

Universal influenza virus vaccines: what can we learn from the human immune response following exposure to H7 subtype viruses?

Stadlbauer D, Nachbagauer R, Meade P, Krammer F.

Front Med. 2017 Dec;11(4):471-479. doi: 10.1007/s11684-017-0602-z. Epub 2017 Nov 20. Review.

PMID:
29159597
14.

Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for In Vivo Protection in a Serum Transfer Mouse Challenge Model.

Jacobsen H, Rajendran M, Choi A, Sjursen H, Brokstad KA, Cox RJ, Palese P, Krammer F, Nachbagauer R.

MBio. 2017 Sep 19;8(5). pii: e01463-17. doi: 10.1128/mBio.01463-17.

15.

Induction of Broadly Cross-Reactive Stalk-Specific Antibody Responses to Influenza Group 1 and Group 2 Hemagglutinins by Natural H7N9 Virus Infection in Humans.

Liu L, Nachbagauer R, Zhu L, Huang Y, Xie X, Jin S, Zhang A, Wan Y, Hirsh A, Tian D, Shi X, Dong Z, Yuan S, Hu Y, Krammer F, Zhang X, Xu J.

J Infect Dis. 2017 Feb 15;215(4):518-528. doi: 10.1093/infdis/jiw608.

16.

Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity.

Bardina SV, Bunduc P, Tripathi S, Duehr J, Frere JJ, Brown JA, Nachbagauer R, Foster GA, Krysztof D, Tortorella D, Stramer SL, García-Sastre A, Krammer F, Lim JK.

Science. 2017 Apr 14;356(6334):175-180. doi: 10.1126/science.aal4365. Epub 2017 Mar 30.

17.

Analysis of Anti-Influenza Virus Neuraminidase Antibodies in Children, Adults, and the Elderly by ELISA and Enzyme Inhibition: Evidence for Original Antigenic Sin.

Rajendran M, Nachbagauer R, Ermler ME, Bunduc P, Amanat F, Izikson R, Cox M, Palese P, Eichelberger M, Krammer F.

MBio. 2017 Mar 21;8(2). pii: e02281-16. doi: 10.1128/mBio.02281-16.

18.

Universal influenza virus vaccines and therapeutic antibodies.

Nachbagauer R, Krammer F.

Clin Microbiol Infect. 2017 Apr;23(4):222-228. doi: 10.1016/j.cmi.2017.02.009. Epub 2017 Feb 12. Review.

19.

Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins.

Nachbagauer R, Choi A, Hirsh A, Margine I, Iida S, Barrera A, Ferres M, Albrecht RA, García-Sastre A, Bouvier NM, Ito K, Medina RA, Palese P, Krammer F.

Nat Immunol. 2017 Apr;18(4):464-473. doi: 10.1038/ni.3684. Epub 2017 Feb 13.

20.

Progesterone-Based Contraceptives Reduce Adaptive Immune Responses and Protection against Sequential Influenza A Virus Infections.

Hall OJ, Nachbagauer R, Vermillion MS, Fink AL, Phuong V, Krammer F, Klein SL.

J Virol. 2017 Mar 29;91(8). pii: e02160-16. doi: 10.1128/JVI.02160-16. Print 2017 Apr 15.

21.

Cross-Reactive and Cross-Neutralizing Activity of Human Mumps Antibodies Against a Novel Mumps Virus From Bats.

Beaty SM, Nachbagauer R, Hirsh A, Vigant F, Duehr J, Azarm KD, Stelfox AJ, Bowden TA, Duprex WP, Krammer F, Lee B.

J Infect Dis. 2017 Jan 15;215(2):209-213. doi: 10.1093/infdis/jiw534.

22.

Broadly Neutralizing Hemagglutinin Stalk-Specific Antibodies Induce Potent Phagocytosis of Immune Complexes by Neutrophils in an Fc-Dependent Manner.

Mullarkey CE, Bailey MJ, Golubeva DA, Tan GS, Nachbagauer R, He W, Novakowski KE, Bowdish DM, Miller MS, Palese P.

MBio. 2016 Oct 4;7(5). pii: e01624-16. doi: 10.1128/mBio.01624-16.

23.

Globular Head-Displayed Conserved Influenza H1 Hemagglutinin Stalk Epitopes Confer Protection against Heterologous H1N1 Virus.

Klausberger M, Tscheliessnig R, Neff S, Nachbagauer R, Wohlbold TJ, Wilde M, Palmberger D, Krammer F, Jungbauer A, Grabherr R.

PLoS One. 2016 Apr 18;11(4):e0153579. doi: 10.1371/journal.pone.0153579. eCollection 2016.

24.

Cryo-electron Microscopy Structures of Chimeric Hemagglutinin Displayed on a Universal Influenza Vaccine Candidate.

Tran EE, Podolsky KA, Bartesaghi A, Kuybeda O, Grandinetti G, Wohlbold TJ, Tan GS, Nachbagauer R, Palese P, Krammer F, Subramaniam S.

MBio. 2016 Mar 22;7(2):e00257. doi: 10.1128/mBio.00257-16.

25.

Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans.

Nachbagauer R, Choi A, Izikson R, Cox MM, Palese P, Krammer F.

MBio. 2016 Jan 19;7(1):e01996-15. doi: 10.1128/mBio.01996-15.

26.

Hemagglutinin Stalk Immunity Reduces Influenza Virus Replication and Transmission in Ferrets.

Nachbagauer R, Miller MS, Hai R, Ryder AB, Rose JK, Palese P, García-Sastre A, Krammer F, Albrecht RA.

J Virol. 2015 Dec 30;90(6):3268-73. doi: 10.1128/JVI.02481-15.

27.

A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice.

Nachbagauer R, Kinzler D, Choi A, Hirsh A, Beaulieu E, Lecrenier N, Innis BL, Palese P, Mallett CP, Krammer F.

NPJ Vaccines. 2016;1. pii: 16015. doi: 10.1038/npjvaccines.2016.15. Epub 2016 Sep 22.

28.

Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains.

Ryder AB, Nachbagauer R, Buonocore L, Palese P, Krammer F, Rose JK.

J Virol. 2015 Dec 16;90(5):2544-50. doi: 10.1128/JVI.02598-15.

29.

Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses.

Wohlbold TJ, Nachbagauer R, Margine I, Tan GS, Hirsh A, Krammer F.

Vaccine. 2015 Jun 26;33(29):3314-21. doi: 10.1016/j.vaccine.2015.05.038. Epub 2015 May 28.

30.

Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice.

Wohlbold TJ, Nachbagauer R, Xu H, Tan GS, Hirsh A, Brokstad KA, Cox RJ, Palese P, Krammer F.

MBio. 2015 Mar 10;6(2):e02556. doi: 10.1128/mBio.02556-14.

31.

A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.

Ryder AB, Buonocore L, Vogel L, Nachbagauer R, Krammer F, Rose JK.

J Virol. 2015 Mar;89(5):2820-30. doi: 10.1128/JVI.03246-14. Epub 2014 Dec 24.

32.

Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans.

Nachbagauer R, Wohlbold TJ, Hirsh A, Hai R, Sjursen H, Palese P, Cox RJ, Krammer F.

J Virol. 2014 Nov;88(22):13260-8. doi: 10.1128/JVI.02133-14. Epub 2014 Sep 10.

33.

Prospective analysis of human cytomegalovirus DNAemia and specific CD8+ T cell responses in lung transplant recipients.

Weseslindtner L, Kerschner H, Steinacher D, Nachbagauer R, Kundi M, Jaksch P, Simon B, Hatos-Agyi L, Scheed A, Klepetko W, Puchhammer-Stöckl E.

Am J Transplant. 2012 Aug;12(8):2172-80. doi: 10.1111/j.1600-6143.2012.04076.x. Epub 2012 Apr 30.

34.

Human cytomegalovirus infection in lung transplant recipients triggers a CXCL-10 response.

Weseslindtner L, Nachbagauer R, Kundi M, Jaksch P, Kerschner H, Simon B, Hatos-Agyi L, Scheed A, Aberle JH, Klepetko W, Puchhammer-Stöckl E.

Am J Transplant. 2011 Mar;11(3):542-52. doi: 10.1111/j.1600-6143.2010.03404.x. Epub 2011 Jan 10.

Supplemental Content

Loading ...
Support Center